These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31532789)

  • 1. Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.
    Carter C; Houser KV; Yamshchikov GV; Bellamy AR; May J; Enama ME; Sarwar U; Larkin B; Bailer RT; Koup R; Chen GL; Patel SM; Winokur P; Belshe R; Dekker CL; Graham BS; Ledgerwood JE;
    PLoS One; 2019; 14(9):e0222178. PubMed ID: 31532789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial.
    Houser KV; Yamshchikov GV; Bellamy AR; May J; Enama ME; Sarwar U; Larkin B; Bailer RT; Koup R; Paskel M; Subbarao K; Anderson E; Bernstein DI; Creech B; Keyserling H; Spearman P; Wright PF; Graham BS; Ledgerwood JE;
    PLoS One; 2018; 13(11):e0206837. PubMed ID: 30388160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial.
    Ledgerwood JE; Bellamy AR; Belshe R; Bernstein DI; Edupuganti S; Patel SM; Renehan P; Zajdowicz T; Schwartz R; Koup R; Bailer RT; Yamshchikov GV; Enama ME; Sarwar U; Larkin B; Graham BS;
    PLoS One; 2015; 10(5):e0125914. PubMed ID: 25950433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults.
    Gorse GJ; Falsey AR; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2015 Feb; 33(9):1151-9. PubMed ID: 25613721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.
    Frenck RW; Belshe R; Brady RC; Winokur PL; Campbell JD; Treanor J; Hay CM; Dekker CL; Walter EB; Cate TR; Edwards KM; Hill H; Wolff M; Leduc T; Tornieporth N
    Vaccine; 2011 Aug; 29(34):5666-74. PubMed ID: 21699951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost.
    Ledgerwood JE; Hu Z; Costner P; Yamshchikov G; Enama ME; Plummer S; Hendel CS; Holman L; Larkin B; Gordon I; Bailer RT; Poretz DM; Sarwar U; Kabadi A; Koup R; Mascola JR; Graham BS;
    Contemp Clin Trials; 2015 Sep; 44():112-118. PubMed ID: 26275339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.
    Frey SE; Bernstein DI; Brady RC; Keitel WA; El Sahly H; Rouphael NG; Mulligan MJ; Atmar RL; Edupuganti S; Patel SM; Dickey M; Graham I; Anderson EL; Noah DL; Hill H; Wolff M; Belshe RB
    Vaccine; 2015 Jan; 33(1):163-73. PubMed ID: 25444805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study.
    Hu Y; Chu K; Lavis N; Li X; Liang B; Liu S; Shao M; Shu JD; Tabar C; Samson S
    Hum Vaccin Immunother; 2019; 15(5):1066-1069. PubMed ID: 30779689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults.
    Rostad CA; Atmar RL; Walter EB; Frey S; Meier JL; Sherman AC; Lai L; Tsong R; Kao CM; Raabe V; El Sahly HM; Keitel WA; Whitaker JA; Smith MJ; Schmader KE; Swamy GK; Abate G; Winokur P; Buchanan W; Cross K; Wegel A; Xu Y; Yildirim I; Kamidani S; Rouphael N; Roberts PC; Mulligan MJ; Anderson EJ
    Clin Infect Dis; 2024 Jun; 78(6):1757-1768. PubMed ID: 38537255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
    Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
    Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
    Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
    DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E
    Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
    Treanor JT; Albano FR; Sawlwin DC; Graves Jones A; Airey J; Formica N; Matassa V; Leong J
    Vaccine; 2017 Apr; 35(15):1856-1864. PubMed ID: 28302411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
    Sesay S; Brzostek J; Meyer I; Donazzolo Y; Leroux-Roels G; Rouzier R; Astruc B; Szymanski H; Toursarkissian N; Vandermeulen C; Kowalska E; Van Damme P; Salamand C; Pepin S
    Hum Vaccin Immunother; 2018 Mar; 14(3):596-608. PubMed ID: 28968138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial.
    Chiu SS; Chan KH; Tu W; Lau YL; Peiris JS
    Vaccine; 2009 Jul; 27(35):4834-9. PubMed ID: 19523908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans.
    Ledgerwood JE; Hu Z; Gordon IJ; Yamshchikov G; Enama ME; Plummer S; Bailer R; Pearce MB; Tumpey TM; Koup RA; Mascola JR; Nabel GJ; Graham BS;
    Clin Vaccine Immunol; 2012 Nov; 19(11):1792-7. PubMed ID: 22956656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults: A Randomized Clinical Trial.
    Schmader KE; Liu CK; Harrington T; Rountree W; Auerbach H; Walter EB; Barnett ED; Schlaudecker EP; Todd CA; Poniewierski M; Staat MA; Wodi P; Broder KR
    JAMA Netw Open; 2021 Jan; 4(1):e2031266. PubMed ID: 33443580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route.
    Patel SM; Atmar RL; El Sahly HM; Cate TR; Keitel WA
    Vaccine; 2010 Apr; 28(17):3025-9. PubMed ID: 19931380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial.
    Bernstein DI; Guptill J; Naficy A; Nachbagauer R; Berlanda-Scorza F; Feser J; Wilson PC; Solórzano A; Van der Wielen M; Walter EB; Albrecht RA; Buschle KN; Chen YQ; Claeys C; Dickey M; Dugan HL; Ermler ME; Freeman D; Gao M; Gast C; Guthmiller JJ; Hai R; Henry C; Lan LY; McNeal M; Palm AE; Shaw DG; Stamper CT; Sun W; Sutton V; Tepora ME; Wahid R; Wenzel H; Wohlbold TJ; Innis BL; García-Sastre A; Palese P; Krammer F
    Lancet Infect Dis; 2020 Jan; 20(1):80-91. PubMed ID: 31630990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination.
    Morelon E; Pouteil Noble C; Daoud S; Cahen R; Goujon-Henry C; Weber F; Laurent PE; Kaiserlian D; Nicolas JF
    Vaccine; 2010 Oct; 28(42):6885-90. PubMed ID: 20709000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.